Supernus Pharma (SUPN) Tops Q4 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Supernus Pharma (SUPN) Tops Q4 EPS by 2c

Supernus Announces Fourth Quarter and Full Year 2019 Financial Results

February 25, 2020 4:41 PM EST

Fourth quarter and full year 2019 total revenue of $100.4 million and $392.8 million, respectively.
Fourth quarter and full year 2019 net product sales of $97.9 million and $383.4 million, respectively.Fourth quarter and full year 2019 operating earnings of $40.8 million and $148.6 million, respectively.FDA assigned PDUFA target action date of November 8, 2020 for review of SPN-812 New Drug Application.Phase III P302 trial of SPN-810 for the treatment of IA in ADHD patients 6 to 11 years old did not meet primary endpoint.

ROCKVILLE, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:... More